1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Valeant Pharmaceuticals International, Inc. - Strategy and SWOT Report

Introduction

Valeant Pharmaceuticals International, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Valeant Pharmaceuticals International, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Valeant Pharmaceuticals International, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Valeant Pharmaceuticals International, Inc. including a breakdown and examination of key business segments

- Intelligence on Valeant Pharmaceuticals International, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Valeant Pharmaceuticals International, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Valeant Pharmaceuticals International, Inc. (Valeant or 'the company’) is a multinational specialty pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. The company markets its products in the US, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa. It is headquartered in Quebec, Canada, and employed approximately 16,800 people as of December 31, 2014. The company recorded revenues of $8,263.5 million during the financial year ended December 2014 (FY2014), an increase of 43.2% over FY2013. The operating profit of the company was $2,039.7 million in FY2014, as compared to an operating loss of $409.5 million in FY2013. The net profit of the company was $913.5 million in FY2014, as compared to a net loss of $866.1 million in FY2013.

Reasons to Purchase:

- Gain understanding of Valeant Pharmaceuticals International, Inc. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Valeant Pharmaceuticals International, Inc. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Valeant Pharmaceuticals International, Inc.’s business structure, strategy and prospects

Table Of Contents

Valeant Pharmaceuticals International, Inc. - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.